Immatics (NASDAQ:IMTX) Stock Price Down 0.2%

Immatics (NASDAQ:IMTX)’s stock price traded down 0.2% during mid-day trading on Tuesday . The company traded as low as $10.64 and last traded at $10.72. 181,219 shares changed hands during trading, a decline of 62% from the average session volume of 471,380 shares. The stock had previously closed at $10.74.

Immatics Stock Down 0.2 %

The company has a market cap of $907.56 million, a price-to-earnings ratio of -8.25 and a beta of 0.69. The firm has a 50-day simple moving average of $11.16 and a 200 day simple moving average of $10.50.

Immatics (NASDAQ:IMTX) last announced its earnings results on Thursday, March 21st. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. The business had revenue of $17.14 million for the quarter, compared to analysts’ expectations of $11.78 million. Immatics had a negative net margin of 179.67% and a negative return on equity of 43.58%. As a group, research analysts expect that Immatics will post -1.44 EPS for the current year.

Institutional Trading of Immatics

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMTX. TD Asset Management Inc lifted its stake in shares of Immatics by 102.8% in the 3rd quarter. TD Asset Management Inc now owns 197,718 shares of the company’s stock worth $2,290,000 after acquiring an additional 100,200 shares during the period. Jump Financial LLC purchased a new position in Immatics during the third quarter worth about $469,000. Lord Abbett & CO. LLC lifted its position in Immatics by 5.6% in the third quarter. Lord Abbett & CO. LLC now owns 513,773 shares of the company’s stock valued at $5,949,000 after purchasing an additional 27,066 shares during the period. Trexquant Investment LP purchased a new stake in Immatics in the 3rd quarter valued at approximately $498,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Immatics during the 3rd quarter worth approximately $3,781,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.